Maastricht标准Ⅲ类心死亡供者供肾移植39例术后早期疗效观察

Early therapeutic efficacy after kidney transplantation from M-Ⅲ type donation after cardiac death in 39 patients

目的探讨Maastricht标准Ⅲ类(M-Ⅲ类)心死亡供者(DCD)供肾移植术后早期疗效。方法 2010年10月至2012年9月,共39例终末期肾病患者在中山大学附属第一医院接受了M-Ⅲ类DCD供肾移植,予常规免疫抑制治疗,观察术后早期移植肾功能恢复和并发症发生情况。结果共8例发生移植肾功能延迟,发生率为20.5%,2例发生急性排斥反应,余29例移植肾功能均在术后1～2周顺利恢复。结论 M-Ⅲ类DCD供肾移植术后早期移植肾功能延迟发生率较高,无严重并发症,总体疗效较满意。

Objective To investigate the early therapeutic efficacy after kidney transplantation from M-Ⅲ type donation after cardiac death （DCD）. Methods From October 2010 to September 2012, a total of 39 patients with end-stage renal diseases received kidney transplantation from M-Ⅲ type DCD and routine immunosuppressive therapy at the First Affiliated Hospital, Sun Yat-sen University. The postoperative early graft function and complications of recipients were observed. Results Delayed graft function （DGF） was noted in 8 patients （20. 5% ）. Two recipients underwent acute rejection. The others recovered smoothly at 1-2 weeks postoperatively. Conclusion The early therapeutic efficacy after kidney transplantation from M-Ⅲ type DCD was satisfactory in the absence of disastrous complications, though the incidence of DGF was somewhat high.